Wedbush Forecasts Strong Price Appreciation for AnaptysBio (NASDAQ:ANAB) Stock

robot
Abstract generation in progress

Wedbush has increased its price target for AnaptysBio (NASDAQ:ANAB) stock to $75 from $60, maintaining an “outperform” rating, indicating a potential 21% upside. Despite a mixed market reaction to its latest earnings beat, the company’s board authorized a $100 million stock buyback program, while insider sales were noted. AnaptysBio, a clinical-stage biotechnology company, focuses on therapeutic antibody development in immunology and inflammation.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin